The present retrospective chart review documents the treatment practice of in-patients suffering from acute manic or hypomanic episodes, at the Department of General Psychiatry, Medical University of Vienna between 1997 and 2001. The aim of the study was to compare the efficacy of typical neuroleptics and atypical antipsychotics as add-on therapy to mood stabilizers. A total of 119 episodes of consecutively admitted patients with ICD-10-defined acute mania (n=106) or hypomania (n=13) were included in a retrospective analysis. Two subgroups were separated out of the whole patient sample according to the medication used : (a) mood stabilizer+typical neuroleptic (n=27) and (b) mood stabilizer+atypical antipsychotic (n=39). The treatment patterns of both subgroups during the first 14 d of in-patient treatment were evaluated. The therapeutic effect was measured by the Clinical Global Impression Scale (CGI). Both patient groups showed no differences on CGI at admission. Patients treated with atypical antipsychotics showed a significantly greater clinical improvement after 14 d (p<0.005) and on discharge (p<0.05) than patients treated with typical neuroleptics. Furthermore, patients treated with atypical antipsychotics developed significantly less extrapyramidal side-effects (p<0.01) and were significantly treated less often with benzodiazepines (p<0.05) during the first 14 d compared to the group receiving typical neuroleptics. Based on our evaluation and the data available in the literature atypical antipsychotics can be considered as first choice for the treatment of acute mania as add-on therapy to mood stabilizers because of their better efficacy and side-effect profile compared to typical neuroleptics.
Introduction
The prevalence of acute manic episodes leading to a hospital stay is 1 % ; the risk for a relapse is 90 % (Svendsen, 1997) . The range of therapeutic interventions recommended includes psychopharmacological treatment with lithium, anticonvulsants, neuroleptics/antipsychotics, tranquillizers/hypnotics and calcium-channel blockers as well as electroconvulsive therapy (Licht, 1998) . Preferably, mood stabilizers like lithium or anticonvulsants are used as first-line treatment for acute mania (APA, 1994) . Nevertheless, newer guidelines show that patients representing subtypes of acute mania do benefit from a combination therapy of a mood stabilizer and a typical neuroleptic or an atypical antipsychotic (Grunze et al., 2003 ; Kasper et al., 1999 ; Sachs et al., 2000) .
Typical neuroleptics have been shown to have antimanic efficacy (Segal et al., 2000 ; Tohen et al., 2001) and are widely used in daily practice (Letmaier et al., 2004) . Furthermore they can be used in an intramuscular injection form in emergency conditions. Nevertheless, the use of typical neuroleptics is problematical because of their unfavourable side-effects, such as extrapyramidal symptoms (EPS) or tardive dyskinesia (TD). Some studies showed that the risk to develop EPS or TD is higher in patients with bipolar disorder compared to those suffering from schizophrenic disorders (Mukherjee et al., 1986 ; Nasrallah et al., 1988) .
ARTICLE
In contrast to typical neuroleptics, atypical antipsychotics have a more advantageous side-effect profile with fewer EPS and less long-term risk of TD (Keck et al., 2000) . In double-blind, controlled studies especially, risperidone and olanzapine have been shown to be effective in the treatment of acute mania (e.g. Hirschfeld et al., 2004 ; Sachs et al., 2002 ; Tohen et al., 2000) . Lately, other atypical antipsychotics like quetiapine, ziprasidone and aripiprazole have been shown to have antimanic properties in randomized, double-blind, placebo-controlled trials and have been recently approved in the USA for bipolar mania (Bowden et al., 2005 ; Keck et al., 2003a,b) .
However, double-blinded, randomized, controlled clinical trials in acute mania provide the problem of a realistic application of the scientific results in daily practice. One reason is the kind of illness itself. Manic patients often tend to act in a manipulative way and, therefore, influence design and method of the investigations (Platman, 1970) . Furthermore, a complex study design may overcharge patients suffering from a severe form of bipolar illness -i.e. consequently less severe illness episodes would be mainly selected (Woggon, 1987) . Retrospective chart analysis about treatment patterns regarding acute mania are important in order to provide basic conditions for further treatment schemes (Mü ller-Oerlinghausen, 1990 ). Moreover, treatment patterns of acute mania are of special interest in the light of the discrepancy between recommendations and daily practice (Chou, 1992) .
The aim of the present study was to compare the efficacy and safety profile of typical neuroleptics and atypical antipsychotics as add-on therapy to mood stabilizers in a clinically relevant setting. To achieve this objective, we reviewed the case histories of all patients who were treated for a manic or hypomanic episode at the Medical University of Vienna, Department of General Psychiatry from 1997 until 2001. Later years were not included in the study because the frequency of prescriptions of atypical antipsychotics increased tremendously and, thus, balanced comparisons of the two subgroups would not have been possible.
Methods

Patients
Patients were diagnosed according to ICD-10 criteria (WHO, 1992) . This diagnostic manual is commonly used at our department in daily practice.
From 1997 until 2001 all consecutively admitted patients suffering from acute mania or hypomania were evaluated in a retrospective chart analysis (n=133). We included all in-patient treatments lasting at least 14 d. Prescriptions of mood stabilizers, antipsychotics/neuroleptics and additionally tranquillizers/benzodiazepines during the first 14 d of inpatient treatment were analysed. Since the focus of this study was to compare typical neuroleptics with atypical antipsychotics as add-on therapy to mood stabilizers, patients who were not treated with this treatment regime were excluded. Mood stabilizers had to be prescribed in a proven efficacious dosage regimen.
A data-file was developed to sum up relevant information from each case history, including demographic data (age, gender), onset of illness, number of earlier manic episodes, occurrence of psychotic features, development of EPS and duration of hospital stay. From the entire patient sample two subgroups could be derived according to medication used : (a) mood stabilizer+typical neuroleptic agents and (b) mood stabilizer+atypical antipsychotic agents (see Figure 1 ). The presence of EPS was recorded when mentioned in either the nurses' or physicians' notes or when the patient received biperidone or procyclidine.
Outcome measures
The two patients groups were compared in terms of duration of hospital stay and development of EPS. In order to monitor the therapeutic effect the mean Clinical Global Impressions -Severity of Illness (CGI-S) score and the mean Clinical Global Impressions -Improvement (CGI-I) score at admission, after 14 d of in-patient treatment and on discharge was calculated. CGI scores were documented weekly by residents in all patients' case histories by reviewing the psychiatrists', residents' and nurses' notes. That means that CGI scores were evaluated prospectively during hospitalization and without the intention of study as part of the routine documentation.
The CGI is a three-item scale used to assess treatment response in psychiatric patients (NIMH, 1970) . The items are : severity of illness, global improvement, and efficacy index. Item 1 is rated on a seven-point scale (1=normal to 7=extremely ill), item 2 is commonly rated on a seven-point scale (1=very much improved to 7=very much worse) and item 3 on a four-point scale (from 'none ' to ' outweighs therapeutic effect ').
In our patient sample the CGI-S ratings were done using the following categories : 1 (normal), 2 (borderline ill), 3 (mildly ill), 4 (moderately ill), 5 (markedly ill), 6 (severely ill), 7 (extremely ill).
In contrast to the existing seven-point CGI-I scale in our patient sample clinical improvement was rated on a four-point rating scale. CGI-I ratings were done to the patients' own baseline severity of illness using the following categories 1 (marked, vast), 2 (moderate, decided), 3 (minimal, slight) and 4 (unchanged, worse).
At our department item 3 (efficacy index) is not routinely rated in daily practice.
Data analysis
For statistical analysis the Statistical Package for Social Sciences, version 11.0 for Windows (SPSS Inc., Chicago, IL, USA) and Excel 5.0 (Microsoft, Redmond, WA, USA) were used. For ANOVA the Student's t test was applied (socio-demographic and illness-related data). For differences in age, onset of illness and duration of hospitalization the Student's t test was used for data analysis. Mean daily dosages of co-medication in both subgroups were compared by Student's t test and differences in frequencies of gender, diagnoses, prescriptions and adverse effects were tested by Pearson's x 2 test. Inter-group comparisons of CGI-S and CGI-I scores were done by Mann-Whitney U tests. To estimate differences of improvement of CGI-S and of changes of CGI-I between admission, after 14 d of in-patient treatment and discharge between subgroups a Friedman analyses (for multiple dependent samples) was performed. For every test the confidence interval was 95 % (p<0.05). All tests were two-tailed.
Results
Selection criteria of subgroups
During the observation period 133 consecutive inpatient treatments of manic or hypomanic episodes were documented. Data of 14 illness episodes had to be excluded because of too short duration of hospital stay (n=11) or because of wrong diagnosis at admission (n=3). The three patients with wrong diagnosis at admission were diagnosed as schizoaffective disorder on discharge. The remaining patients had different reasons for the shorter duration of hospital stay. One patient died and three patients left in-patient treatment shortly after admission against medical advice. Two patients were diagnosed as bipolar disorder, mixed episode and five patients were diagnosed as bipolar disorder, hypomanic episode and on average their hospital stay lasted between 1 d and 7 d.
Overall, in the present study data of 90 patients (119 episodes), who received in-patient treatment over a period of more than 14 d have been included. Of these, two subgroups were separated out of the whole patient sample according to the medication used : (a) mood stabilizer+typical neuroleptic(s) (n=27) with or without concomitantly administered benzodiazepines and (b) mood stabilizer+atypical antipsychotic(s) (n=39) with or without benzodiazepines. Illness episodes which have been treated with mood stabilizers alone (n=3), with mood stabilizer+low potency neuroleptics (n=20) or with a mood stabilizer+atypical antipsychotics+typical neuroleptics (n=22) were excluded (see Figure 1) . 
Demographic and illness-related data of subgroups
There were no significant differences in age (p=0.89) and gender (p=0.59) between the subgroups. There were no significant differences in distribution of diagnoses (p=0.70), onset of illness (p=0.59), number of previous episodes (p=0.20) duration of hospital stay (p=0.07) or confinement (p=0.36) between subgroups (see Tables 1-3) .
Treatment patterns
The frequency of prescriptions of typical neuroleptics and atypical antipsychotics in both subgroups is shown in Table 4 . There were no significant differences in frequency of prescriptions of mood stabilizers between both groups (p>0.05, see Table 5 ). All patients received benzodiazepines during the first 14 d. Regarding the dosage of benzodiazepines used during the first 14 d, patients treated with an atypical antipsychotic+mood stabilizer needed significantly less (p=0.002) co-medication (diazepam equivalent) with benzodiazepines per day compared to the group treated with a typical neuroleptic+mood stabilizer (Table 5) .
Severity of illness
At admission the CGI severity of illness did not differ significantly between subgroups (p=0.82). After 14 d patients treated with atypical antipsychotics showed a significant higher reduction of CGI-S scores compared to the group with typical neuroleptics (p<0.01). In addition, there was a significant difference in outcome of in-patient treatment, too. Patients who received atypical antipsychotics showed significantly less severe CGI-S scores (p=0.007) at discharge than patients treated with typical neuroleptics. (For further details see Table 6 .)
Improvement of illness
As a further outcome measure for the efficacy of psychopharmacological treatment an adapted four-point CGI-I score was used (for details see the Methods section). Fourteen days after admission 4 % of the patients treated with a typical neuroleptic+mood stabilizer showed a moderate, and 26 % a minimal, improvement of symptoms. A total of 70 % remained unchanged or changed for worse. In contrast, 13 % of all patients treated with an atypical antipsychotic+mood stabilizer showed a moderate improvement, 54 % a minimal improvement of symptoms and 33 % remained unchanged or changed for worse.
On discharge from the group treated with a typical neuroleptic+mood stabilizer 33 % of the patients showed a marked, 52 % a moderate and 11 % a minimal improvement of symptoms. One patient remained unchanged. From the group treated with an atypical antipsychotic+mood stabilizer 62 % showed a marked, 31 % a moderate and 7 % a minimal improvement of symptoms. No patient remained unchanged or changed for worse.
In conclusion there were significant differences in CGI-I scores between subgroups. Patients treated with atypical antipsychotics showed significantly more clinical improvement after 14 d (Z=x2.93, p=0.003) of in-patient treatment and on discharge (Z=x2.21, p=0.03) compared to patients treated with typical neuroleptics.
Adverse events : EPS
Patients treated with typical neuoleptics developed significantly more EPS than the group treated with atypical antipsychotics (p<0.01). There was a slight gender difference between both groups. Women out of the typical neuroleptic agent group showed significantly more EPS than women in the atypical antipsychotic drug group (p=0.002) compared to men (p=0.034). (For further details see Table 7 .)
Discussion
The starting point for the present study was an earlier conducted study where the authors compared the pharmacological treatment patterns of in-patients suffering from acute mania in the time period between 1997 and 1999 with published treatment algorithms ( Letmaier et al., 2004) . The results of this previous study reflected that international guidelines (Goldberg, 2000) have not been included in daily practice, e.g. monotherapy with a mood stabilizer, and polypharmacy was the predominant treatment scheme. Complementary to older guidelines, latest treatment algorithms (e.g. Grunze et al., 2003 ; Sachs et al., 2000) recommend a combination therapy of a mood stabilizer with either an atypical antipsychotic or a typical neuroleptic for some subtypes of acute mania. As the results of the earlier study (Letmaier et al., 2004) in the period from 1997 to 1999 indicated that patients might benefit from a combination therapy of a mood stabilizer and a typical neuroleptic or an atypical antipsychotic (measured by the reduction of CGI scores at admission and on discharge) and later guidelines do recommend this treatment scheme for acute mania, the authors enlarged the existing data pool by adding the years 2000 and 2001 and conducted the current chart analysis in order to verify if there is a difference in efficacy and tolerability of typical neuroleptics and atypical antipsychotics as add-on therapy to an existing mood stabilizer treatment after 14 d of in-patient treatment.
Overall, the strengths of the present study are the large number (n=119) of illness episodes reported as well as the fact that patients were seen routinely in clinical practice. Furthermore, a consecutive collection of illness episodes during a fixed period was done and the data (e.g. socio-demographic issues, illness-related factors) evaluated was quite detailed, especially the description of the treatment patterns used. In addition, the ratings of the CGI scores at admission, after 14 d, and on discharge were done prospectively during hospitalization and without the intention of the present study.
One limitation concerns the fact that the study was retrospective, lacking a randomized assignment. Additionally, as mentioned above, the main objective of the present study was to compare the efficacy and tolerability of the treatment scheme mood stabilizer+ atypical antipsychotics with the treatment scheme mood stabilizer+typical neuroleptics. A 'mood stabilizer alone ' subgroup would have strengthened the results of our study but unfortunately the 'mood stabilizer alone ' subgroup was too small to use in our calculations (see Figure 1) . However, the naturalistic study design of the study included patients who were consecutively admitted at our department and to whom outpatient settings (e.g. monotherapy with a mood stabilizer) failed to handle their mostly moderate or severe form of bipolar mania.
As shown in Figure 1 two other treatment subgroups were available namely a ' mood stabilizer+ typical neuroleptics+atypical antipsychotic ' subgroup and a 'mood stabilizer+low-potency neuroleptics ' subgroup. We excluded these two subgroups as the main objective was to compare the efficacy and tolerability of atypical antipsychotics and typical neuroleptics to an existing, adequate mood stabilizer therapy. Moreover, we did not calculate the therapeutic effect and safety profile of the subgroup 'mood stabilizer+typical neuroleptics+atypical subgroup' One episode (n, %) 3 (7.7) 7 (25.9) Two episodes (n, %) 5 (12.8) 1 (3. since a clear statement cannot be made as to whether atypical antipsychotics or typical neuroleptics, which were added to a mood stabilizer, had a therapeutic effect in this subgroup. In addition, we also excluded the 'mood stabilizer+low potency neuroleptics ' subgroup since to our knowledge there are no controlled clinical trials showing low-potency neuroleptics to be effective in the treatment of bipolar mania. Nevertheless, lowpotency neuroleptics are widely used off-label in daily practice (e.g. Letmaier et al., 2004 ; Licht, 1998) . Regarding the aspect of frequent off-label usage, another reason why we excluded this group was that the prescriptions of low-potency neuroleptics were quite heterogeneous (eight different substances), therefore, no serious statements about treatment options could have been made. Besides these methodological aspects, owing to the small number, no special calculations for the hypomanic episodes were carried out. A further limitation might be the fact that the choice of medication was determined individually by physicians, thus, a selection bias can not be excluded.
Despite these limitations the study contains interesting findings. First, there was no significant difference in severity of illness at admission between subgroups. This fact makes both groups comparable regarding the therapeutic effects of the treatment schemes which were used (see Tables 4 and 5 ). In addition, all patients received mood stabilizers in an efficacious dosage regimen (see Table 5 ). However, after 14 d of in-patient treatment the clinical improvement, measured by an adapted four-point CGI-I scale, of patients treated with atypical antipsychotics was significantly greater than those treated with typical neuroleptics. Moreover, on discharge patients treated with atypical antipsychotics showed a significantly greater clinical improvement than those treated with typical neuroleptics.
To our knowledge, there is only one study with a similar study design and methodology (Miller et al., 2001) . In contrast to our study, the two subgroups used by Miller et al. had different CGI-S scores at admission (the group treated with atypical antipsychotic was less severely ill). Similar to our results patients treated with atypical antipsychotics showed a significant better clinical improvement after 14 d of inpatient treatment as well as on discharge than patients treated with typical neuroleptics.
In addition, in our patient sample subjects treated with atypical antipsychotics needed significantly less co-medication with benzodiazepines than patients treated with typical neuroleptics. This is of particularly importance since prescriptions of benzodiazepines might induce further drug abuse and it is known that bipolar patients with comorbid diagnosis of drug abuse may have a more severe illness course than others (Cassidy et al., 2001) .
When adverse side-effects were compared patients treated with atypical antipsychotics had a significantly lower risk for developing EPS than patients treated with typical neuroleptics. This is a crucial problem since studies showed that patients with bipolar disorder exhibit a higher frequency of neurolepticinduced dystonia or TD compared to patients suffering from schizophrenia (Mukherjee et al., 1986 ; Nasrallah et al., 1988) .
Finally, patients treated with atypical antipsychotics showed a tendency for a shorter duration of hospitalization, which is particularly interesting in terms of reducing costs for in-patient treatments.
Therefore, atypical antipsychotics may be a better choice than typical neuroleptics in the treatment of acute mania due to their better efficacy and sideeffect profile compared to typical neuroleptics. In addition, recent studies also show that atypical antipsychotics may improve depressed mood, whereas typical neuroleptics can worsen it (Tohen et al., 1999) .
But how should patients suffering from a severe form of acute mania be treated if they refuse oral medication and need to be treated with an intramuscular formulation? A short time ago, typical neuroleptics were the only treatment option for these patients. Recently, in Austria a short-acting intramuscular formulation of olanzapine has been approved for bipolar mania. Furthermore, the atypical antipsychotic ziprasidone has also been approved in a short-acting intramuscular formulation for the treatment of psychotic agitation. In the future intramuscular formulations of atypical antipsychotics might play a more important role in the treatment of severe forms of mania. Consequently, prospective trials should be conducted comparing patients treated with intramuscular formulations of typical neuroleptics vs. atypical antipsychotics as add-on therapy to mood stabilizers to evaluate the therapeutic efficacy and safety profile of this treatment option for severe types of mania.
Conclusion
Based on our evaluation and data available in literature (e.g. Bowden et al., 2005 ; Kasper et al., 2002 ; Keck et al., 2003a,b ; Sachs et al., 2002 ; Segal et al., 2000 ; Tohen et al., 1999) atypical antipsychotics can be considered as the first choice as add-on therapy for the treatment of acute mania compared to typical neuroleptics due to their better efficacy, the significantly reduced need of co-medication using benzodiazepines, the significantly less frequency of extrapyramidal side-effects and a tendency for a shorter duration of hospital stay.
